Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3331655 | Hematology/Oncology Clinics of North America | 2007 | 10 Pages |
Abstract
The treatment of early or limited-stage Hodgkin's lymphoma continues to evolve. With the likelihood of cure of the lymphoma approaching 95% it has become increasingly necessary to balance improved effectiveness of treatment with minimization of troublesome late toxicity. Carefully crafted treatment strategies based on optimal combinations of brief chemotherapy and involved-field radiation or even reliance on brief chemotherapy alone for carefully selected patients have emerged as the most attractive approaches to achieve this important balance.
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
David A. Macdonald, Joseph M. Connors,